Evolution of MS lesions to black holes under DNA vaccine treatment

Journal of Neurology

Volumn 259, Issue 7, 2012, Pages 1375-1382

  Papadopoulou, Athina ^a   Von Felten, Stefanie ^a   Traud, Stefan ^a   Rahman, Amena ^b   Quan, Joanne ^b   King, Robert ^b   Garren, Hideki ^b   Steinman, Lawrence ^c   Cutter, Gary ^d   Kappos, Ludwig ^a   Radue, Ernst Wilhelm ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b Bayhill Therapeutics   (United States)

^c STANFORD UNIVERSITY   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

BHT 3009; DNA vaccine; Multiple sclerosis; Persistent black holes

Indexed keywords

BHT 3009; DNA VACCINE; MYELIN BASIC PROTEIN; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; BRAIN DAMAGE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PERSISTENT BLACK HOLE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN M; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MYELIN BASIC PROTEIN; ODDS RATIO; TIME FACTORS; VACCINES, DNA; YOUNG ADULT;

EID: 84864286671     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-011-6361-x     Document Type: Article

References (35)

1. Barkhof F, Brueck W, De Groot C et al (2003) Remyelinated lesions in multiple sclerosis magnetic resonance image appearance. Arch Neurol 60:1073-1081 (Pubitemid 36975794)
2. Bitsch A, Kuhlmann T, Stadelmann C, Lassmann H, Lucchinetti C, Bruck W (2001) A longitudinal MRI study of histopathologically defined hypointense multiple sclerosis lesions. Ann Neurol 49:793-796 (Pubitemid 32530247)
3. Brueck W, Bitsch A, Kolenda H, Brück Y, Stiefel M, Lassmann H (1997) Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. Ann Neurol 42:783-793 (Pubitemid 27481551)
4. van Walderveen MA, Kamphorst W, Scheltens P et al (1998) Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology 50:1282-1288 (Pubitemid 28240340)
5. Bitsch A, Bruhn H, Vougioukas V et al (1999) Inflammatory CNS demyelination: histopathologic correlation with in vivo quantitative proton MR spectroscopy. Am J Neuroradiol 20:1619-1627 (Pubitemid 29498612)
6. Karampekios S, Papanikolaou N, Papadaki E et al (2005) Quantification of magnetization transfer rate and native T1 relaxation time of the brain: correlation with magnetization transfer ratio measurements in patients with multiple sclerosis. Neuroradiology 47:189-196 (Pubitemid 40778824)
7. Levesque I, Sled JG, Narayanan S et al (2005) The role of edema and demyelination in chronic T1 black holes: a quantitative magnetization transfer study. J Magn Reson Imaging 21:103-110
8. Otaduy MC, Callegaro D, Bacheschi LA, Leite CC (2006) Correlation of magnetization transfer and diffusion magnetic resonance imaging in multiple sclerosis. Mult Scler 12:754-759 (Pubitemid 46111767)
9. Rovira A, Alonso J, Cucurella G et al (1999) Evolution of multiple sclerosis lesions on serial contrast-enhanced T1-weighted and magnetization-transfer MR images. Am J Neuroradiol 20:1939-1945
10. van Waesberghe JH, van Buchem MA, Filippi M et al (1998) MR outcome parameters in multiple sclerosis: comparison of surfacebased thresholding segmentation and magnetization transfer ratio histographic analysis in relation to disability (a preliminary note). Am J Neuroradiol 19:1857-1862 (Pubitemid 30409565)
11. van Walderveen MA, Barkhof F, Pouwels PJ, van Schijndel RA, Polman CH, Castelijns JA (1999) Neuronal damage in T1-hypointense multiple sclerosis lesions demonstrated in vivo using proton magnetic resonance spectroscopy. Ann Neurol 46:79-87 (Pubitemid 29314385)
12. Iannucci G, Minicucci L, Rodegher M, Sormani MP, Comi G, Filippi M (1999) Correlations between clinical and MRI involvement in multiple sclerosis: assessment using T(1), T(2) and MT histograms. J Neurol Sci 171:121-129
13. Minneboo A, Uitdehaag BM, Jongen P et al (2009) Association between MRI parameters and the MS severity scale: a 12 year follow-up study. Mult Scler 15:632-637
14. Nijeholt GJ, van Walderveen MA, Castelijns JA et al (1998) Brain and spinal cord abnormalities in multiple sclerosis. Correlation between MRI parameters, clinical subtypes and symptoms. Brain 121(Pt 4):687-697 (Pubitemid 28162129)
15. Rovaris M, Comi G, Rocca MA et al (1999) Relevance of hypointense lesions on fast fluid-attenuated inversion recovery MR images as a marker of disease severity in cases of multiple sclerosis. Am J Neuroradiol 20:813-820 (Pubitemid 29536256)
16. Sailer M, Losseff NA, Wang L, Gawne-Cain ML, Thompson AJ, Miller DH (2001) T1 lesion load and cerebral atrophy as a marker for clinical progression in patients with multiple sclerosis. A prospective 18 months follow-up study. Eur J Neurol 8:37-42 (Pubitemid 32154572)
17. Truyen L, van Waesberghe JH, van Walderveen MA et al (1996) Accumulation of hypointense lesions ("black holes") on T1 spinecho MRI correlates with disease progression in multiple sclerosis. Neurology 47:1469-1476 (Pubitemid 26422538)
18. van Walderveen MA, Barkhof F, Hommes OR et al (1995) Correlating MRI and clinical disease activity in multiple sclerosis: relevance of hypointense lesions on short-TR/short-TE (T1-weighted) spin-echo images. Neurology 45:1684-1690
19. van Walderveen MA, Truyen L, van Oosten BW et al (1999) Development of hypointense lesions on T1-weighted spin-echo magnetic resonance images in multiple sclerosis: relation to inflammatory activity. Arch Neurol 56:345-351 (Pubitemid 29120233)
20. van Walderveen MA, Lycklama ANG, Ader HJ et al (2001) Hypointense lesions on T1-weighted spin-echo magnetic resonance imaging: relation to clinical characteristics in subgroups of patients with multiple sclerosis. Arch Neurol 58:76-81 (Pubitemid 32053210)
21. Zivadinov R, Leist TP (2005) Clinical-magnetic resonance imaging correlations in multiple sclerosis. J Neuroimaging 15:10S-21S (Pubitemid 43010528)
22. van Waesberghe JH, van Walderveen MA, Castelijns JA et al (1998) Patterns of lesion development in multiple sclerosis: longitudinal observations with T1-weighted spin-echo and magnetization transfer MR. Am J Neuroradiol 19:675-683 (Pubitemid 30422711)
23. Rovira A, Leon A (2008) MR in the diagnosis and monitoring of multiple sclerosis: an overview. Eur J Radiol 67:409-414
24. Dalton CM, Miszkiel KA, Barker GJ et al (2004) Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis. J Neurol 251:407-413 (Pubitemid 38501297)
25. Filippi M, Rovaris M, Rocca MA, Sormani MP, Wolinsky JS, Comi G (2001) Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes". Neurology 57:731-733 (Pubitemid 32783013)
26. Barkhof F, Hulst HE, Drulovic J, Uitdehaag BM, Matsuda K, Landin R (2010) MN166-001 Investigators. Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant? Neurology 74(13):1033-1040
27. MacManus DG, Miller D, Kappos L, et al (2008) The effect of BG00012 on conversion of gadolinium-enhancing lesions to T1-hypointense lesions. Mult Scler 14:163
28. Garren H, Robinson WH, Krasulova E et al (2008) Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis. Ann Neurol 63:611-620
29. Garren H, Robinson WH, Rahman A, King R, Utz PJ, Steinman L (2010) Baseline plasma anti-MBP antibody levels correlate with subject response to BHT-3009, a novel, antigen-specific tolerizing DNA vaccine therapy for MS patients. Mult Scler p417
30. Frohman EM, Racke MK, Raine CS (2006) Multiple sclerosis-the plaque and its pathogenesis. N Engl J Med 354:942-955
31. Sospedra M, Martin R (2005) Immunology of multiple sclerosis. Annu Rev Immunol 23:683-747 (Pubitemid 40563183)
32. Genain CP, Cannella B, Hauser SL, Raine CS (1999) Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat Med 5:170-175 (Pubitemid 29068523)
33. Bielekova B, Goodwin B, Richert N et al (2000) Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med 6:1167-1175
34. Cadavid D, Cheriyan J, Skurnick J, Lincoln JA, Wolansky LJ, Cook SD (2009) New acute and chronic black holes in patients with multiple sclerosis randomised to interferon beta-1b or glatiramer acetate. J Neurol Neurosurg Psychiatry 80:1337-1343
35. Dalton CM, Miszkiel KA, Barker GJ et al (2004) Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis. J Neurol 251:407-413 (Pubitemid 38501297)